Biogen Buys Pfizer Neuropsychiatry Candidate for Up-to-$590M+

Biogen said today it will expand its neuroscience pipeline into neuropsychiatry by agreeing to acquire from Pfizer the Phase II-ready cognitive impairment associated with schizophrenia (CIAS) candidate PF-04958242 for up to $590 million-plus.PF-04958242 is an α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator designed to facilitate neurotransmission. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process that can